{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:31Z","timestamp":1740107431674,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00393-022-01157-w","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T20:02:59Z","timestamp":1642708979000},"page":"136-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["So behandle ich\u00a0\u2013 die Polymyalgia rheumatica mit m\u00f6glichst geringer kumulativer Glukokortikoiddosis","This is how I treat\u2014Polymyalgia rheumatica with a cumulative dosage of glucocorticoids as low as possible"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6184-1757","authenticated-orcid":false,"given":"Jens Gert","family":"Kuipers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"issue":"10","key":"1157_CR1","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco\u00a0C, Singh\u00a0YP, Perel\u00a0P, Hutchings\u00a0A, Camellino\u00a0D, Mackie\u00a0S, Abril\u00a0A, Bachta\u00a0A, Balint\u00a0P, Barraclough\u00a0K, Bianconi\u00a0L, Buttgereit\u00a0F, Carsons\u00a0S, Ching\u00a0D, Cid\u00a0M, Cimmino\u00a0M, Diamantopoulos\u00a0A, Docken\u00a0W, Duftner\u00a0C, Fashanu\u00a0B, Gilbert\u00a0K, Hildreth\u00a0P, Hollywood\u00a0J, Jayne\u00a0D, Lima\u00a0M, Maharaj\u00a0A, Mallen\u00a0C, Martinez-Taboada\u00a0V, Maz\u00a0M, Merry\u00a0S, Miller\u00a0J, Mori\u00a0S, Neill\u00a0L, Nordborg\u00a0E, Nott\u00a0J, Padbury\u00a0H, Pease\u00a0C, Salvarani\u00a0C, Schirmer\u00a0M, Schmidt\u00a0W, Spiera\u00a0R, Tronnier\u00a0D, Wagner\u00a0A, Whitlock\u00a0M, Matteson\u00a0EL, Dasgupta\u00a0B (2015) 2015\u00a0recommendations for the management of polymyalgia rheumatica: a European league against rheumatism\/American college of rheumatology collaborative initiative. Ann Rheum Dis 74(10):1799\u20131807. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207492","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1157_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00393-018-0476-8","volume":"77","author":"F Buttgereit","year":"2018","unstructured":"Buttgereit\u00a0F, Brabant\u00a0T, Dinges\u00a0H, Hiemer\u00a0I, Kaplani\u00a0M, Kiltz\u00a0U, Kyburz\u00a0D, Rei\u00dfhauer\u00a0A, Schneider\u00a0M, Weseloh\u00a0C, Dejaco\u00a0C (2018) S3\u00a0guidelines on treatment of polymyalgia rheumatica : evidence-based guidelines of the German society of rheumatology (DGrh), the Austrian society of rheumatology and rehabilitation (OGR) and the Swiss society of rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z\u00a0Rheumatol 77(5):429\u2013441. https:\/\/doi.org\/10.1007\/s00393-018-0476-8","journal-title":"Z Rheumatol"},{"issue":"1","key":"1157_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sarh.2000.8366","volume":"30","author":"F Cantini","year":"2000","unstructured":"Cantini\u00a0F, Salvarani\u00a0C, Olivieri\u00a0I, Macchioni\u00a0L, Ranzi\u00a0A, Niccoli\u00a0L, Padula\u00a0A, Boiardi\u00a0L (2000) Erythrocyte sedimentation rate and C\u2011reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 30(1):17\u201324. https:\/\/doi.org\/10.1053\/sarh.2000.8366","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"1157_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/ard.48.8.658","volume":"48","author":"V Kyle","year":"1989","unstructured":"Kyle\u00a0V, Hazleman\u00a0BL (1989) Treatment of\u00a0polymyalgia\u00a0rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 48(8):658\u2013661. https:\/\/doi.org\/10.1136\/ard.48.8.658","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"1157_CR5","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit\u00a0F, Dejaco\u00a0C, Matteson\u00a0EL, Dasgupta\u00a0B (2016) Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315(22):2442\u20132458. https:\/\/doi.org\/10.1001\/jama.2016.5444","journal-title":"JAMA"},{"key":"1157_CR6","unstructured":"De Miguel E, Macchion P, Conticin E, Campochiaro C, Karalilova R, Klinowski G, Falsetti P, Monjo I, Tomeller A, Batalov Z, Hocevar A (2021) Subclinical large vessel vasculitis in polymyalgia rheumatica. https:\/\/acrabstracts.org\/abstract\/subclinical-large-vessel-vasculitis-in-polymyalgia-rheumatica\/ (Abstract 0466, ACR convergence 2021). Zugegriffen: 12.11.2021"},{"issue":"10","key":"1157_CR7","first-page":"2143","volume":"29","author":"G Myklebust","year":"2002","unstructured":"Myklebust\u00a0G, Wilsgaard\u00a0T, Jacobsen\u00a0BK, Gran\u00a0JT (2002) No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398\u00a0cases and matched population controls. J\u00a0Rheumatol 29(10):2143\u20132147","journal-title":"J Rheumatol"},{"issue":"3","key":"1157_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/art.10402","volume":"47","author":"G Haugeberg","year":"2002","unstructured":"Haugeberg\u00a0G, Dovland\u00a0H, Johnsen\u00a0V (2002) Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum 47(3):346\u2013347. https:\/\/doi.org\/10.1002\/art.10402","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1157_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00124743-199612000-00002","volume":"2","author":"JE Naschitz","year":"1996","unstructured":"Naschitz\u00a0JE, Slobodin\u00a0G, Yeshurun\u00a0D, Rozenbaum\u00a0M, Rosner\u00a0I (1996) A polymyalgia rheumatica-like syndrome as presentation of metastatic cancer. J\u00a0Clin Rheumatol 2(6):305\u2013308. https:\/\/doi.org\/10.1097\/00124743-199612000-00002","journal-title":"J Clin Rheumatol"},{"issue":"20","key":"1157_CR10","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/archinte.1997.00440410115014","volume":"157","author":"JE Naschitz","year":"1997","unstructured":"Naschitz\u00a0JE, Slobodin\u00a0G, Yeshurun\u00a0D, Rozenbaum\u00a0M, Rosner\u00a0I (1997) Atypical polymyalgia rheumatica as a\u00a0presentation of metastatic cancer. Arch Intern Med 157(20):2381","journal-title":"Arch Intern Med"},{"issue":"2","key":"1157_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5152\/eurjrheum.2016.039","volume":"4","author":"C Korkmaz","year":"2017","unstructured":"Korkmaz\u00a0C, Y\u0131ld\u0131z\u00a0P (2017) Giant cell arteritis,\u00a0polymyalgia\u00a0rheumatica, and late-onset rheumatoid arthritis: can they be components of a single disease process in elderly patients? Eur J Rheumatol 4(2):157\u2013160. https:\/\/doi.org\/10.5152\/eurjrheum.2016.039","journal-title":"Eur J Rheumatol"},{"issue":"4","key":"1157_CR12","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1093\/rheumatology\/ken343","volume":"27","author":"CT Pease","year":"2009","unstructured":"Pease\u00a0CT, Haugeberg\u00a0G, Montague\u00a0B, Hensor\u00a0EMA, Bhakta\u00a0BB, Thomson\u00a0W, Ollier\u00a0WER, Morgan\u00a0AW (2009) Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a\u00a05-yr prospective study. Clin Exp Rheumatol 27(4):S139\u201345. https:\/\/doi.org\/10.1093\/rheumatology\/ken343","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"1157_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RBM, Bijlsma\u00a0JWJ, Burmester\u00a0GR, Dougados\u00a0M, Kerschbaumer\u00a0A, McInnes\u00a0IB, Sepriano\u00a0A, van Vollenhoven\u00a0RF, de Wit\u00a0M, Aletaha\u00a0D, Aringer\u00a0M, Askling\u00a0J, Balsa\u00a0A, Boers\u00a0M, den Broeder\u00a0AA, Buch\u00a0MH, Buttgereit\u00a0F, Caporali\u00a0R, Cardiel\u00a0MH, De Cock\u00a0D, Codreanu\u00a0C, Cutolo\u00a0M, Edwards\u00a0CJ, van Eijk-Hustings\u00a0Y, Emery\u00a0P, Finckh\u00a0A, Gossec\u00a0L, Gottenberg\u00a0JE, Lund Hetland\u00a0M, Huizinga\u00a0TWJ, Koloumas\u00a0M, Li\u00a0Z, Mariette\u00a0X, M\u00fcller-Ladner\u00a0U, Mysler\u00a0EF, da Silva\u00a0JAP, Po\u00f3r\u00a0G, Pope\u00a0JE, Rubbert-Roth\u00a0A, Ruyssen-Witrand\u00a0A, Saag\u00a0KG, Strangfeld\u00a0A, Takeuchi\u00a0T, Voshaar\u00a0M, Westhovens\u00a0R, van der Heijde\u00a0D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1157_CR14","first-page":"S139","volume":"27","author":"I Olivieri","year":"2009","unstructured":"Olivieri\u00a0I, Pipitone\u00a0N, D\u2019Angelo\u00a0S, Padula\u00a0A, Salvarani\u00a0C (2009) Late-onset\u00a0rheumatoid arthritis and\u00a0late-onset\u00a0spondyloarthritis. Clin Exp Rheumatol 27(4):S139\u201345","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1157_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00393-013-1344-1","volume":"73","author":"M Talke","year":"2014","unstructured":"Talke\u00a0M, Schmidt\u00a0WA (2014) Polymyalgia\u00a0rheumatica\u00a0in daily routine practice. Z\u00a0Rheumatol 73(5):408\u2013414. https:\/\/doi.org\/10.1007\/s00393-013-1344-1","journal-title":"Z Rheumatol"},{"issue":"344","key":"1157_CR16","doi-asserted-by":"publisher","first-page":"e1408","DOI":"10.1136\/bmj.e1408","volume":"28","author":"T Helliwell","year":"2012","unstructured":"Helliwell\u00a0T, Muller\u00a0S, Hider\u00a0S (2012) ESR\u00a0can be\u00a0normal\u00a0in giant cell arteritis and\u00a0polymyalgia\u00a0rheumatica. BMJ 28(344):e1408. https:\/\/doi.org\/10.1136\/bmj.e1408 (author reply e1409)","journal-title":"BMJ"},{"key":"1157_CR17","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie (2014) Therapiebogen Methotrexat. https:\/\/dgrh.de\/dam\/jcr:0fff25d9-b2ea-4fca-94bc-06b03a0e09fd\/methotrexat_arzt_2014_07.pdf. Zugegriffen: 04.12.2021"},{"issue":"2","key":"1157_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/ard.45.2.136","volume":"45","author":"M De Silva","year":"1986","unstructured":"De Silva\u00a0M, Hazleman\u00a0BL (1986) Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45(2):136\u2013138. https:\/\/doi.org\/10.1136\/ard.45.2.136","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1157_CR19","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1742-1241.2012.02981.x","volume":"66","author":"T Adizie","year":"2012","unstructured":"Adizie\u00a0T, Christidis\u00a0D, Dharmapaliah\u00a0C, Borg\u00a0F, Dasgupta\u00a0B (2012) Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a\u00a0case series. Int J Clin Pract 66(9):906\u2013909. https:\/\/doi.org\/10.1111\/j.1742-1241.2012.02981.x","journal-title":"Int J Clin Pract"},{"key":"1157_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/120638","author":"AP Diamantopoulos","year":"2013","unstructured":"Diamantopoulos\u00a0AP, Hetland\u00a0H, Myklebust\u00a0G (2013) Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. https:\/\/doi.org\/10.1155\/2013\/120638","journal-title":"Biomed Res Int"},{"issue":"1","key":"1157_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.semarthrit.2013.01.003","volume":"43","author":"P Macchioni","year":"2013","unstructured":"Macchioni\u00a0P, Boiardi\u00a0L, Catanoso\u00a0M, Pulsatelli\u00a0L, Pipitone\u00a0N, Meliconi\u00a0R, Salvarani\u00a0C (2013) Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 43(1):113\u2013118. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.01.003","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"1157_CR22","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally\u00a0L, Forbess\u00a0L, Hatzis\u00a0C, Spiera\u00a0R (2016) Brief report: a prospective open-label lphase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol 68(10):2550\u20132554. https:\/\/doi.org\/10.1002\/art.39740","journal-title":"Arthritis. Rheumatol."},{"key":"1157_CR23","doi-asserted-by":"crossref","unstructured":"Bonelli M, Radner H, Smolen J, Durechova M, Stieger J, Husic R, Kerschbaumer A, Dejaco C, Aletaha D (2021) Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE)\u2014a\u00a0phase 2\/3 randomized controlled trial. https:\/\/acrabstracts.org\/abstract\/tocilizumab-in-patients-with-new-onset-polymyalgia-rheumatica-pmr-spare-a-phase-2-3-randomized-controlled-trial\/ (Abstract number 0507, ACR convergence 2021). Zugegriffen: 04.12.2021","DOI":"10.1136\/annrheumdis-2021-221126"},{"issue":"12","key":"1157_CR24","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/1756-185X.13723","volume":"22","author":"K Chino","year":"2019","unstructured":"Chino\u00a0K, Kondo\u00a0T, Sakai\u00a0R, Saito\u00a0S, Okada\u00a0Y, Shibata\u00a0A, Kurasawa\u00a0T, Okuyama\u00a0A, Takei\u00a0H, Amano\u00a0K (2019) Tocilizumab\u00a0monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study. Int J Rheum Dis 22(12):2151\u20132157. https:\/\/doi.org\/10.1111\/1756-185X.13723","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"1157_CR25","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec\u00a0V, Berthelot\u00a0JM, Cornec\u00a0D, Renaudineau\u00a0Y, Marhadour\u00a0T, Jousse-Joulin\u00a0S, Querellou\u00a0S, Garrigues\u00a0F, De Bandt\u00a0M, Gouillou\u00a0M, Saraux\u00a0A (2016) Efficacy of first-line\u00a0tocilizumab\u00a0therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis 75(8):1506\u20131510. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208742","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01157-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01157-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01157-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T10:19:00Z","timestamp":1646302740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01157-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01157-w","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"18 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr die letzten 3\u00a0Jahre gibt J.G. Kuipers Beratungst\u00e4tigkeiten bzw. Honorare f\u00fcr Vortragst\u00e4tigkeit an f\u00fcr AbbVie, AOK Bremen, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Chugai, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda, UCB und Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diese \u00dcbersichtsarbeit wurden keine Studien an Menschen oder Tieren vom Autor durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort benannten ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}